Forian Inc. · NASDAQ:FORA
Forian — Roth Conference March 2022
17 slides from Forian's conference presentation, Mar 15, 2022
Slide 1: Roth Conference March 2022 Corporate Overview
Roth ConferenceMarch 2022 Corporate Overview
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements ofte
Slide 3: What We Do
What We Do 3 by coupling innovative software and data technologies we enable customers with their customer, product and market insights that optimize their operational, clinical and financial performance. Mission Leverage data to improve health outcomes and business value
Slide 4: Forian at a Glance
Forian at a Glance 4 $18-$19M+2021ERevenue1 $200M Market Capitalization3 290M+Patients Covered in HIPAA Database #2 Seed-to-Sale Market Share2 5B+Annual Mx & Rx Claimsin Database $3.4B+Cannabis GMVProcessed Annually #2Point-of-Sale Market Share2 1. Full year, Pro Forma $8.2MM 1H21 and 2H21 Revenue G
Slide 5: Proven Leadership, Tested Results
Proven Leadership, Tested Results 5 Max WygodCo-Founder and Executive Chairman Adam Dublin Co-Founder and Chief Strategy Officer Dan Barton Chief Executive Officer Michael VeseyChief Financial Officer Edward Spaniel, Jr.Executive Vice President & General Counsel Martin WygodSerial Founder / Chairman
Slide 6: Corporate History
Corporate History 6 Data driven decisionsHIPAA-compliant Data/Data Science PlatformData management and analytics tools powered by machine learningLeader in data privacyExpertise in SaaS based information, data platforms and commercial, clinical and operational analytics Medical Outcomes Research Ana
Slide 7: Data Assets
Data AssetsCreate value by connecting what is grown to the outcomes users expect CULTIVATOR MANUFACTURER POINT-OF-SALE PHARMACY CLAIMS HOSPITAL EMR DATA CUSTOMERDEMOGRAPHIC DATA MEDICAL CLAIMS PATIENT-REPORTED OUTCOMES* *HIPAA compliance across consumer journey 5B+ Annual Mx or Rx Claims 11 Governme
Slide 8: A Growing Product Portfolio
A Growing Product Portfolio Products supporting revenue generation State Regulatory ComplianceStatewide tracking, enforcement and monitoring system to ensure transparency and accountability Dispensary Point of SaleCompliance, inventory management, customer profiles, CRM, loyalty programs, online ord
Slide 9: Analytics That Move Brands
Analytics That Move Brands 9 Basket AnalysesBrand InsightsCommercial AnalyticsCustomer SegmentationData ManagementForecastingMarket ComparisonsMarketing ActivationPatient RegistriesPatient JourneyPrice OptimizationReal World Evidence Maturing the Analytics in an Immature Market
Slide 10: Unparalleled Insights
Unparalleled Insights 10 Anxiolytics Opioids NSAIDS Sedatives Betablockers Anti-Spastics Psychostimulants Antidepressant Mood Stabilizers Opioid Antagonists Sativa Hybrid/Mixed Sativa Dominant Hybrids Indica Dominant Hybrids Actual Analysis on 2.5 Million linked Consumers to their Medical Diagnoses
Slide 11: Emerging PharmaCannabinoid Market
Emerging PharmaCannabinoid Market 11 Serving the convergence of two large and growing markets US Cannabis$24B2 Growing 15% CAGR (39 legal states and D.C.) US Life Sciences & HCIT$400B1 Growing 11% CAGR 1. Pharmaceutical Manufacturing Market Size, Grand View Research 7/20212. US Review: Exceptional G
Slide 12: Continued Investment and Growth
Continued Investment and Growth 12 Quarterly Revenues(Pro Forma Consolidated) Continued to organically scale healthcare information product business, which contributed approximately $4 million in revenue for the nine months ended September 30, 2021, compared to $0.335 million in 2020 Completed merge
Slide 13: % FORIAN
% FORIAN 4 2022 Forian Inc. Confidential and Proprietary
Slide 14: Appendix
pendix ZF % FORIAN 2022 Forian Inc. Confidential and Proprietary ?
Slide 15: Reconciliation of U.S. GAAP to Non-GAAP Financial Measures
15 Reconciliation of U.S. GAAP to Non-GAAP Financial Measures l
Slide 16: Reconciliation of U.S. GAAP to Non-GAAP Financial Measures
Reconciliation of U.S. GAAP to Non-GAAP Financial Measures l This presentation includes a non-GAAP measure, which we define as financial information that has not been prepared in accordance with U.S. GAAP. The non-U.S. GAAP financial measure provided herein is earnings before interest, taxes, non-ca
Slide 17: 17
17